Senseonics Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 9, 2020, details a series of material definitive agreements entered into by Senseonics Holdings, Inc. (the "Company"). The filings focus on a strategic partnership for the commercialization of the Company's continuous glucose monitoring systems and a concurrent capital raise to fund operations and repay existing debt.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as it is a current report regarding specific events rather than a periodic financial statement. However, it outlines significant changes to the Company's capital structure:
- Debt Financing: The Company agreed to borrow $35.0 million in aggregate principal through the issuance of Senior Secured Convertible Notes to PHC Holdings Corporation ("PHC").
- Debt Repayment: The Company intends to use $17.6 million of the proceeds to repay in full its First Lien Notes due October 2021.
- Equity Issuance: The Company agreed to issue 2,941,176 shares of common stock to PHC as a financing fee. Additionally, the Company agreed to sell 3,000 shares of Series A Convertible Preferred Stock to Masters Special Situations, LLC at $1,000 per share (totaling $3.0 million), with an option for Masters to purchase up to an additional 27,000 shares.
- Interest Rates: The new Notes carry an annual interest rate of 9.5%, which may decrease to 8.0% upon FDA approval of the Eversense XL product.
- Outstanding Debt: As of August 8, 2020, approximately $9.9 million in principal of Second Lien Notes remained outstanding.
Material Changes and Agreements
The Company executed three primary agreements on August 9, 2020:
- Ascensia Collaboration and Commercialization Agreement:
- Ascensia Diabetes Care Holdings AG (an affiliate of PHC) received the exclusive right to distribute the Eversense and Eversense XL systems worldwide, subject to specific territorial exceptions for existing partners (Roche, Rubin Medical) until 2021 or 2022.
- Ascensia will receive a portion of net revenue at tiered percentages ranging from the mid-teens to the mid-forties based on global net revenue levels.
- Ascensia is obligated to meet minimum annual revenue targets and sales/marketing spend levels.
- The agreement has an initial term of five years from the Product Availability Date for Eversense XL, with potential extensions.
- Note Purchase Agreement with PHC:
- Issuance of $35.0 million in Senior Secured Convertible Notes maturing October 31, 2024.
- Notes are convertible at approximately $0.54 per share.
- Includes an option for the Company to sell up to $15.0 million of convertible preferred stock to PHC by December 31, 2022, contingent on FDA approval and stockholder approval.
- Stock Purchase Agreement with Masters:
- Issuance of Series A Convertible Preferred Stock at a conversion price of $0.476 per share.
- Includes registration rights and investor rights allowing Masters to designate a board member if they hold at least 5% of common stock on an as-converted basis.
- Amendment to Second Lien Note Agreement:
- Highbridge Tactical Credit Master Fund, L.P. agreed to extend the maturity date of the Second Lien Notes to August 9, 2023.
- Conversion price for Second Lien Notes set at 90% of the greater of the daily VWAP or $0.33 per share.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The Company intends to use the new capital to repay existing debt and support the commercialization of its products through the Ascensia partnership. The agreements are contingent on regulatory approvals, specifically the FDA approval of the 180-day Eversense XL system, which is a condition for certain interest rate reductions and preferred stock issuances.
Risks and Contingencies:
- Regulatory Risk: The Commercialization Agreement is terminable by Ascensia if Eversense XL is not approved in the U.S. by August 31, 2021.
- Liquidity and Covenants: The Note Purchase Agreement includes financial covenants requiring the Company to operate within an approved budget and achieve minimum revenue and liquidity targets.
- Dilution: The issuance of convertible notes and preferred stock, along with financing fee shares, introduces significant potential dilution to existing common stockholders.
- Change of Control: Various agreements contain termination rights or redemption triggers in the event of a change of control.
Key Facts for Investor Verification
- Verify the status of the FDA marketing approval for the 180-day Eversense XL system, as this triggers interest rate reductions and preferred stock options.
- Confirm the closing of the $35.0 million Note Purchase Agreement and the subsequent repayment of the First Lien Notes.
- Monitor the Company's ability to meet the minimum revenue and liquidity covenants required by the new Note Purchase Agreement.
- Review the specific territorial exclusions in the Ascensia agreement to understand the scope of the Company's retained distribution rights in Europe, Asia, and Latin America.
- Assess the potential dilution impact from the conversion of the $35.0 million Notes (approx. $0.54/share) and the Series A Preferred Stock (approx. $0.476/share).